Skip to content
Open access

Tandem repeat expansions in DAPK1, ANK3, and RPL14 are associated with diverse neurodegenerative diseases

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

Findings identify candidate risk loci for neurodegenerative disease that may expand the contribution of TREs to neurodegenerative disease beyond known repeat expansion disorders.

Abstract

Tandem repeat expansions (TREs) cause over 50 neurological conditions, yet their contribution to neurodegenerative disease risk at a population scale remains incompletely characterized. We performed a TRE association study across 6,539 short tandem repeat loci in 276,411 individuals from the UK Biobank and 44,370 individuals from the All of Us Research Program, using two composite neurodegenerative phenotypes to increase statistical power and capture pleiotropic effects. Meta-analysis across the two cohorts identified associations at eight established pathogenic TRE loci, including C9orf72, DMPK, HTT, ATXN2, ATXN3, CACNA1A, CNBP, and PPP2R2B, recovering known disease-associated expansions from short-read sequencing data at biobank scale. We also identified candidate associations at three additional loci. An intronic AATAA expansion in DAPK1 reached significance (q = 0.0045), with fine-mapping and conditional analysis supporting the repeat as the likely variant underlying the association. An intronic ATTTT expansion in ANK3 (q = 0.034) was observed exclusively in individuals of African and Latino/admixed American ancestry, underscoring the importance of ancestrally diverse cohorts for genetic discovery. An exonic polyalanine expansion in RPL14 was also significant (q = 0.039), where longer alleles were consistently associated with reduced RPL14 expression across independent datasets. Together, these findings identify candidate risk loci for neurodegenerative disease that may expand the contribution of TREs to neurodegenerative disease beyond known repeat expansion disorders.

Read PDF

Similar papers

Open access Sep 2026

Unified long-read panel for Parkinson’s and repeat expansion disorders

In this study, we designed a gene panel based on Nanopore long-read sequencing using adaptive sampling, targeting n = 564 genes associated with Parkinson’s disease (PD) and repeat expansion disorders. We investigated its diagnostic utility in n = 18 patients with (1) pathogenic variants in LRRK2, PRKN, SNCA, and RAB32...

A. Fienemann, J. C. Prietzsche, Joshua Laβ et al. · 0 citations
Open access Sep 2026

ATXN8OS Intermediate Expansion Acts as a Genetic Modifier in Spinocerebellar Ataxia Type 48 (SCA48/STUB1).

BACKGROUND Association between monoallelic STUB1 variant and expanded ATXN8OS alleles was recently reported, suggesting a pathogenic interaction that may influence spinocerebellar ataxia type 48 (SCA48) phenotype. OBJECTIVES We investigated the frequency and clinical impact of ATXN8OS in a large cohort of STUB1 carri...

Charlotte Mouraux, Jean-Loup Méreaux, C. Davoine et al. · 0 citations
Open access Sep 2026

A proteome atlas of structural variation and VNTR effects on complex traits and diseases

Structural variants (SVs), including variable number tandem repeats (VNTRs), are a major source of human genetic variation, but their impact on the proteome remains poorly characterized. Using a long-read assembly-based reference panel, we imputed 54,578 general SVs and 15,826 VNTRs in 54,306 UK Biobank participants to...

P. Yuan, W. Bai, J. Hou et al. · 0 citations
Open access Sep 2026

Association of TYK2 rs2304256 and rs12720270 single-nucleotide polymorphisms with COVID-19 severity

Variability in COVID-19 disease severity suggests that host genetic factors influence immune responses and disease outcomes. Tyrosine kinase 2 (TYK2), encoded by the TYK2 gene, helps regulate immune responses and inflammation. However, the impacts of its variants on disease progression remain unclear. This study invest...

Arindita Das, Md. Tarek Monoyar Hossain, Nazmul Ahsan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.